Compounds > 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea
Page last updated: 2024-08-22

1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea and Acute Myelogenous Leukemia

1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea has been researched along with Acute Myelogenous Leukemia in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Larson, R; Le Beau, MM; Leichman, L; Levin, B; Shepard, KV1

Other Studies

1 other study(ies) available for 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea and Acute Myelogenous Leukemia

ArticleYear
Acute leukemia occurring after radiotherapy and chemotherapy with a nitrosourea, PCNU.
    Investigational new drugs, 1988, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nitrosourea Compounds; Rectal Neoplasms; Translocation, Genetic

1988